JP2008508886A - 活性ボツリヌス毒素ａ型の発現の最適化 - Google Patents

活性ボツリヌス毒素ａ型の発現の最適化 Download PDF

Info

Publication number
JP2008508886A
JP2008508886A JP2007525034A JP2007525034A JP2008508886A JP 2008508886 A JP2008508886 A JP 2008508886A JP 2007525034 A JP2007525034 A JP 2007525034A JP 2007525034 A JP2007525034 A JP 2007525034A JP 2008508886 A JP2008508886 A JP 2008508886A
Authority
JP
Japan
Prior art keywords
open reading
reading frame
cell
seq
active bont
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007525034A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008508886A5 (enExample
Inventor
ランス・イー・スチュワード
マーセラ・エイ・ギルモア
エスター・エ・フェルナンデス−サラス
シェンウェン・リ
ロナルド・ジー・ミラー
ケイ・ロジャー・アオキ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35355531&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2008508886(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of JP2008508886A publication Critical patent/JP2008508886A/ja
Publication of JP2008508886A5 publication Critical patent/JP2008508886A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2007525034A 2004-08-04 2005-08-03 活性ボツリヌス毒素ａ型の発現の最適化 Pending JP2008508886A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59912104P 2004-08-04 2004-08-04
PCT/US2005/027917 WO2006017749A2 (en) 2004-08-04 2005-08-03 Optimizing expression of active botulinum toxin type a

Publications (2)

Publication Number Publication Date
JP2008508886A true JP2008508886A (ja) 2008-03-27
JP2008508886A5 JP2008508886A5 (enExample) 2008-09-18

Family

ID=35355531

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007525034A Pending JP2008508886A (ja) 2004-08-04 2005-08-03 活性ボツリヌス毒素ａ型の発現の最適化

Country Status (6)

Country Link
US (2) US20080057575A1 (enExample)
EP (1) EP1773874B1 (enExample)
JP (1) JP2008508886A (enExample)
AU (1) AU2005271372B2 (enExample)
CA (1) CA2575994A1 (enExample)
WO (1) WO2006017749A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018502580A (ja) * 2015-01-09 2018-02-01 イプセン・バイオイノベーション・リミテッドＩｐｓｅｎ Ｂｉｏｉｎｎｏｖａｔｉｏｎ Ｌｉｍｉｔｅｄ 陽イオン性神経毒
JP2021517825A (ja) * 2018-01-30 2021-07-29 チルドレンズ メディカル センター コーポレーションＣｈｉｌｄｒｅｎ’Ｓ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ Ｃｏｒｐｏｒａｔｉｏｎ Ｂａｃｉｌｌｕｓ系を用いたボツリヌスニューロトキシンの生産

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7514088B2 (en) 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
EP1773874B1 (en) * 2004-08-04 2012-10-24 Allergan, Inc. Optimizing expression of active botulinum toxin type a
CA2588758C (en) 2004-11-22 2017-01-03 New York University Genetically engineered clostridial genes, proteins encoded by the engineered genes, and uses thereof
DK1926744T4 (en) 2005-09-19 2019-01-28 Allergan Inc CLOSTRIDIUM TOXIN-ACTIVABLE CLOSTRIDIAL TOXINES
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
WO2007142954A2 (en) * 2006-05-30 2007-12-13 Dow Global Technologies Inc. Codon optimization method
EP2167119B1 (en) 2007-06-14 2016-08-24 The Secretary of State for Health Chemically modified peptides with improved immunogenicity
KR20160103551A (ko) 2008-12-10 2016-09-01 알러간, 인코포레이티드 클로스트리디움 독소 약제학적 조성물
EP2218783A1 (en) 2009-02-05 2010-08-18 Merz Pharma GmbH & Co. KGaA Novel method for the manufacturing of neurotoxins
JP5826635B2 (ja) 2009-03-13 2015-12-02 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 免疫系調節エンドペプチターゼ活性アッセイ
CA2784666A1 (en) 2009-12-16 2011-11-17 Allergan, Inc. Modified clostridial toxins comprising an integrated protease cleavage site-binding domain
EP2528941A4 (en) * 2010-01-25 2013-05-29 Univ New York FOR TRANSPORT STUDIES AND NEURONAL ADMINISTRATION, MANIPULATED RECOMBINANT DERIVATIVES FROM BOTULINUM NEUROTOXINES
CA2788074C (en) 2010-01-25 2016-07-12 Allergan, Inc. Methods of intracellular conversion of single-chain proteins into their di-chain form
KR101920094B1 (ko) 2010-11-23 2018-11-19 알러간, 인코포레이티드 효모에서 엔테로키나아제를 생산하는 조성물과 방법
US20120244188A1 (en) 2011-03-25 2012-09-27 Allergan, Inc. Treatment of Sensory Disturbance Disorders
US20120251574A1 (en) 2011-03-28 2012-10-04 Allergan, Inc. Endopeptidase and Neurotoxin Combination Treatment of Multiple Medical Conditions
US20120251573A1 (en) 2011-03-28 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Neuroendocrine Disorders
US20120251575A1 (en) 2011-03-28 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Involuntary Movement Disorders
US20120251519A1 (en) 2011-03-29 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Smooth Muscle Disorders
WO2012135304A1 (en) 2011-03-29 2012-10-04 Allergan, Inc. Vagal nerve-based disorders
US20120251518A1 (en) 2011-03-29 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Sexual Dysfunction Disorders
US20120251515A1 (en) 2011-03-29 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Cosmesis Disorders
AU2012255746B2 (en) * 2011-05-17 2016-04-28 Boston Scientific Neuromodulation Corporation User-defined graphical shapes used as a visualization aid for stimulator programming
WO2012174123A1 (en) 2011-06-13 2012-12-20 Allergan, Inc. Treatment of psychological trauma
WO2013091895A1 (en) 2011-12-23 2013-06-27 Merz Pharma Gmbh & Co. Kgaa Novel method for the manufacturing of di-chain proteins for use in humans
US20130171122A1 (en) 2011-12-29 2013-07-04 Allergan, Inc. Endopeptidase and neurotoxin combination treatment of bladder disorders
MX381995B (es) 2012-11-21 2025-03-13 Ipsen Bioinnovation Ltd Métodos para la producción de polipéptidos procesados proteolíticamente.
US9315549B2 (en) 2013-01-28 2016-04-19 New York University Treatment methods using atoxic neurotoxin derivatives
AU2014240116B2 (en) * 2013-03-15 2016-12-15 The Trustees Of The University Of Pennsylvania Mono or multivalent botulinum neurotoxin based vaccine using the heavy chain from serotypes of Clostridium botulinum
EP3113792B1 (en) 2014-03-05 2018-12-05 Merz Pharma GmbH & Co. KGaA Novel recombinant clostridial neurotoxins with increased duration of effect
EP3230457B1 (en) 2014-12-09 2021-06-30 New York University Clostridial neurotoxin fusion proteins, propeptide fusions, their expression, and use
CN107207586B (zh) 2014-12-19 2021-07-13 莫茨药物股份两合公司 用于测定BoNT/E在细胞中的生物活性的装置和方法
TW201718627A (zh) 2015-06-11 2017-06-01 梅茲製藥有限兩合公司 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞
EP3405480B1 (en) 2016-01-20 2022-08-03 Merz Pharma GmbH & Co. KGaA Novel recombinant clostridial neurotoxins with increased duration of effect
ES2893838T3 (es) 2016-03-02 2022-02-10 Merz Pharma Gmbh & Co Kgaa Composición que comprende toxina botulínica
EP3290437A1 (en) 2016-08-31 2018-03-07 Merz Pharma GmbH & Co. KGaA Novel recombinant clostridial neurotoxins with decreased duration of effect
HUE046449T2 (hu) 2016-09-13 2020-03-30 Allergan Inc Stabilizált, nem fehérje eredetû, clostridiális toxin készítmények
EP3312193A1 (en) 2016-10-19 2018-04-25 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum neurotoxins with accelerated onset of effect
EP3333179A1 (en) 2016-12-07 2018-06-13 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum toxin with accelarated onset of effect
EP3335719A1 (en) 2016-12-14 2018-06-20 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum neurotoxins with a stabilized light chain
EP3642222A1 (en) 2017-06-20 2020-04-29 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum toxin with increased duration of effect
EP3649143B1 (en) 2017-07-06 2022-08-31 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum neurotoxins with increased duration of effect
US20210008156A1 (en) 2017-10-26 2021-01-14 Merz Pharma Gmbh & Co. Kgaa Novel recombinant botulinum neurotoxins with increased duration of effect
EP3713595A1 (en) 2017-11-22 2020-09-30 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum toxin with increased duration of effect
US11707510B2 (en) * 2018-02-16 2023-07-25 Preclinics Discovery Gmbh Nucleic acid-based botulinum neurotoxin for therapeutic use
US11959069B2 (en) * 2019-02-28 2024-04-16 Proteonic Biotechnology Ip B.V. Self-immolative plasmid backbone
US20240158773A1 (en) * 2021-03-15 2024-05-16 Children's Medical Center Cprporation Engineered botulinum neurotoxin a protease domain with improved efficacy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000067700A2 (en) * 1999-05-12 2000-11-16 United States Army Medical Research & Materiel Cmd Recombinant vaccine against botulinum neurotoxin
JP2003137897A (ja) * 1994-10-24 2003-05-14 Promega Corp 可溶性組換えボツリヌス毒素タンパク

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2003383A1 (en) * 1988-11-23 1990-05-23 Sushil G. Devare Synthetic dna derived recombinant hiv antigens
UA48104C2 (uk) * 1991-10-04 2002-08-15 Новартіс Аг Фрагмент днк, який містить послідовність,що кодує інсектицидний протеїн, оптимізовану для кукурудзи,фрагмент днк, який забезпечує направлену бажану для серцевини стебла експресію зв'язаного з нею структурного гена в рослині, фрагмент днк, який забезпечує специфічну для пилку експресію зв`язаного з нею структурного гена в рослині, рекомбінантна молекула днк, спосіб одержання оптимізованої для кукурудзи кодуючої послідовності інсектицидного протеїну, спосіб захисту рослин кукурудзи щонайменше від однієї комахи-шкідника
US7037680B2 (en) * 1993-09-21 2006-05-02 The United States Of America As Represented By The Secretary Of The Army Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
US7214787B1 (en) * 1993-09-21 2007-05-08 United States Of America As Represented By The Secretary Of The Army Recombinant vaccine against botulinum neurotoxin
US6114148C1 (en) * 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
WO1999002677A1 (en) * 1997-07-11 1999-01-21 Chugai Seiyaku Kabushiki Kaisha Gene originating in human chondrocyte
US6277622B1 (en) * 1997-08-11 2001-08-21 The University Of Sydney Synthetic polynucleotides
US6218188B1 (en) * 1997-11-12 2001-04-17 Mycogen Corporation Plant-optimized genes encoding pesticidal toxins
US6214602B1 (en) * 1998-08-28 2001-04-10 Promega Corporation Host cells for expression of clostridial toxins and proteins
US6399857B1 (en) * 1999-09-22 2002-06-04 Paradigm Genetics, Inc. Modified nucleotide sequence encoding a LexA DNA binding domain optimized for arabidopsis species
CA2424216A1 (en) * 2000-10-04 2002-04-11 The Trustees Of The University Of Pennsylvania Compositions and methods of using capsid protein from flaviviruses and pestiviruses
TW200403338A (en) * 2002-07-16 2004-03-01 Advisys Inc Codon optimized synthetic plasmids
EP1773874B1 (en) * 2004-08-04 2012-10-24 Allergan, Inc. Optimizing expression of active botulinum toxin type a

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003137897A (ja) * 1994-10-24 2003-05-14 Promega Corp 可溶性組換えボツリヌス毒素タンパク
WO2000067700A2 (en) * 1999-05-12 2000-11-16 United States Army Medical Research & Materiel Cmd Recombinant vaccine against botulinum neurotoxin

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GENE, vol. 315, JPN6011005605, 2003, pages 21 - 32, ISSN: 0001840341 *
TOXICON, vol. 36, no. 11, JPN6011005607, 1998, pages 1539 - 1548, ISSN: 0001840342 *
TRENDS. BIOTECHNOL., vol. 22, no. 7, JPN6011005611, July 2004 (2004-07-01), pages 346 - 353, ISSN: 0001840343 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018502580A (ja) * 2015-01-09 2018-02-01 イプセン・バイオイノベーション・リミテッドＩｐｓｅｎ Ｂｉｏｉｎｎｏｖａｔｉｏｎ Ｌｉｍｉｔｅｄ 陽イオン性神経毒
JP2021517825A (ja) * 2018-01-30 2021-07-29 チルドレンズ メディカル センター コーポレーションＣｈｉｌｄｒｅｎ’Ｓ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ Ｃｏｒｐｏｒａｔｉｏｎ Ｂａｃｉｌｌｕｓ系を用いたボツリヌスニューロトキシンの生産

Also Published As

Publication number Publication date
EP1773874A2 (en) 2007-04-18
AU2005271372A1 (en) 2006-02-16
AU2005271372B2 (en) 2012-05-03
US20090023198A1 (en) 2009-01-22
CA2575994A1 (en) 2006-02-16
US20080057575A1 (en) 2008-03-06
EP1773874B1 (en) 2012-10-24
WO2006017749A3 (en) 2006-03-30
WO2006017749A2 (en) 2006-02-16

Similar Documents

Publication Publication Date Title
EP1773874B1 (en) Optimizing expression of active botulinum toxin type a
US7825233B2 (en) Optimizing expression of active Botulinum Toxin type E
DK1926744T4 (en) CLOSTRIDIUM TOXIN-ACTIVABLE CLOSTRIDIAL TOXINES
EP2178905B1 (en) Methods of activiting clostridial toxins
EP1784420A1 (en) Degradable clostridial toxins
CA2657521A1 (en) Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells
US20110111483A1 (en) Optimizing Expression of Active Botulinum Toxin Type E
US20130245227A1 (en) Methods of activating clostridial toxins
AU2012211346A1 (en) Optimizing expression of active botulinum toxin type A
AU2013204638A1 (en) Optimizing expression of active botulinum toxin type A
AU2012201413A1 (en) Clostridial toxin activatable clostridial toxins

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080730

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080730

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110509

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110516

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110608

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110615

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110707

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110714

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111018